BOSTON, MA, November 09, 2026 /24-7PressRelease/ -- Robert Moore has been recognized for achievement in biomedical research.

Dr. Moore's distinguished career in biomedical research and pharmaceutical business development is marked by a series of pivotal roles across leading organizations in the industry. Since 2025, he has served as senior director of business development at Zhejiang Tianyu Pharmaceutical Co. Ltd., where he is responsible for all sales and marketing activities in North America and West Africa. His oversight includes business and corporate development for North America, developing products and services tailored to evolving market needs, leading marketing initiatives such as trade shows and digital campaigns, and driving both sales and revenue growth.

Among Dr. Moore's most notable achievements in this capacity is leading the company's expansion of access to quality pharmaceuticals in West Africa, a region with a population of 469 million that he regards as historically underserved by the pharmaceutical sector. This initiative builds on earlier work with Quantoom Biosciences, where he addressed global mRNA vaccine access inequity, including undertaking a personal trip to Liberia. Dr. Moore also played a key role in advancing sustainability at TNU, guiding all five manufacturing sites to achieve DSPTI sustainability target validations.

From 2023 to 2024, Dr. Moore was senior director of business development at Quantoom Biosciences. There, he contributed to efforts aimed at reducing disparities in vaccine accessibility worldwide, further cementing his reputation for establishing market presence from the ground up for companies entering new territories. Between 2022 and 2023, he was chief executive officer at RLM BioPharma Consulting, LLC, where he provided strategic guidance and leadership for clients navigating complex biopharmaceutical markets.

As vice president of business development at Medicilon USA Corp., Shanghai, China, from 2021 to 2022, Dr. Moore led initiatives focused on expanding client relationships and identifying new collaboration opportunities. Earlier in 2021, he held the role of vice president of sales at Primera in Princeton, New Jersey, where he drove sales strategies and revenue generation.

Between 2018 and 2021, Dr. Moore served as business development director at Smithers in Gaithersburg, Maryland. He was responsible for creating and implementing commercialization strategies while managing client relationships within the biotechnology sector. From 2015 to 2018, as sales director for the Northeast region at Cryoport Inc. in Irvine, California, he was directly involved in helping develop Good Distribution Practices standards for cell and gene therapy logistics — an industry milestone that has shaped best practices globally.

Dr. Moore's earlier roles include business development account executive at BioAgilytix Labs from 2014 to 2015; director of marketing and sales at MMS Diagnostics LLC from 2012 to 2014; and director of business development at Foresight Science & Technology Inc. from 2011 to 2012. His transition into industry followed more than 12 years of laboratory research — first as a doctoral candidate and postdoctoral fellow at the Cancer Center within Boston University's Office of Research from 2005 to 2011, then as a research technician at Dana-Farber Cancer Institute in Boston between 2003 and 2005.

Over the course of his career, Dr. Moore has built more than $150 million in sales and overseen projects acquired by major pharmaceutical companies for more than $463 million. His expertise spans biomedical research; small- and large-molecule discovery; nucleotide-based therapeutic and vaccine development; ADME and DMPK; regulated and non-regulated bioanalytical testing; CMC; cGMP formulation development; and clinical development and commercialization. He is also skilled in corporate management, research collaboration negotiation, bioanalytical supply chain and logistics, competitive intelligence, and the creation of commercialization strategies for biotechnology organizations.

A testament to his dedication to the field, Dr. Moore has maintained active memberships in several professional organizations, including the American Association of Pharmaceutical Scientists since 2014, as well as MassBio and GBMSDG since 2012. He was also affiliated with AUTM from 2011 to 2013.

Dr. Moore's academic foundation includes a Doctor of Philosophy in microbiology and immunology through the dual degree program at Boston University in 2010. He previously earned dual Bachelor of Arts degrees in biology and East Asian studies from Colby College in 2003. These academic achievements have been instrumental throughout his career by equipping him with both scientific rigor and cross-cultural perspective necessary for global pharmaceutical leadership.

Reflecting on his career, Dr. Moore attributes his strong work ethic to his grandfather's legacy — a man who migrated north during the Great Migration with limited formal education but worked thirty-four years without missing a day — as well as his mother's dedication as a special education teacher for thirty-four years in Wisconsin. He credits his natural curiosity and scientific aptitude alongside mentorship received throughout his academic journey as critical influences on his professional trajectory.

After completing his postdoctoral fellowship in 2011 following more than twelve years working at the laboratory bench as a technician, graduate student and postdoctoral researcher, Dr. Moore discovered an aptitude for business development. His ability to communicate credibly with biotech companies about their technical requirements, while bridging scientific problem-solving with commercial strategy, set him apart in the field.

Dr. Moore's contributions extend beyond direct business achievements into authorship and thought leadership within the life sciences sector. He authored "Intelligent Logistics: Key Considerations of Manufacturing Biologics," published by European Pharmaceutical Manufacturing Magazine in 2017, as well as "Packaging, IT and Cold-Chain Logistics Advances for the Future of Medicine and Clinical Trials," featured by Applied Clinical Trials that same year.

As a co-author on two articles published by the Journal of Endocrinology in 2012 — "SIRT1 Represses Estrogen Signaling, Ligand-Independent ERa-Mediated Transcription, and Cell Proliferation in Breast Cells" and "SIRT1 and Steroid Hormone Receptor Activity" — Dr. Moore contributed original research findings to the field of endocrinology. Earlier, he was a contributing author on "The bHLH Transcription Factor Olig1 Is Required for Repair of Demyelinated Lesions in the CNS," published in Science in 2004.

Recognition for Dr. Moore's accomplishments includes being named Chronic Disease and Anti-Cancer Drugs Supplier of the Year by Life Science Review in 2026. He received first-place honors through the Henry I. Russek Student Achievement Award at Boston University in 2010 as well as the Freeman Asia Scholarship Award in 2001.

Outside his professional endeavors, Dr. Moore remains deeply engaged with community service rooted in his Midwestern upbringing. Alongside his mother and son — who has developed an interest in robotics — he volunteers regularly with The Sanctuary in Milwaukee under Sister McCannon Brown's leadership to provide food, medical care and support services to homeless residents across underserved neighborhoods.

Looking ahead, Dr. Moore aims to continue expanding access to quality medicine across West Africa through TNU while raising industry-wide focus on sustainability initiatives that reduce costs without compromising quality standards. He is committed to leveraging emerging technologies that streamline pharmaceutical development processes so that more patients worldwide may benefit through strengthened international partnerships.

# # #